Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.

Sakai H, Tsurutani J, Iwasa T, Komoike Y, Sakai K, Nishio K, Nakagawa K.

Breast Cancer. 2018 Apr 26. doi: 10.1007/s12282-018-0861-9. [Epub ahead of print]

PMID:
29700710
2.

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.

Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T.

Breast. 2018 Aug;40:67-75. doi: 10.1016/j.breast.2018.04.010. Epub 2018 Apr 23.

PMID:
29698927
3.

Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer.

Ueda H, Takeda M, Ueda S, Kawakami H, Okuno T, Takegawa N, Hayashi H, Tsurutani J, Tamura T, Ishikawa K, Nishimura Y, Nakagawa K.

Oncotarget. 2017 May 17;8(46):80286-80294. doi: 10.18632/oncotarget.17925. eCollection 2017 Oct 6.

4.

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).

Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K.

BMC Cancer. 2017 Oct 6;17(1):674. doi: 10.1186/s12885-017-3664-z.

5.

Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer.

Matsuoka H, Makimura C, Koyama A, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.

Biomed Rep. 2017 Oct;7(4):380-384. doi: 10.3892/br.2017.963. Epub 2017 Aug 8.

6.

Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid.

Yanae M, Fujimoto S, Tane K, Tanioka M, Fujiwara K, Tsubaki M, Yamazoe Y, Morishima Y, Chiba Y, Takao S, Komoike Y, Tsurutani J, Nakagawa K, Nishida S.

J Bone Oncol. 2017 Aug 31;8:18-22. doi: 10.1016/j.jbo.2017.08.004. eCollection 2017 Sep.

7.

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.

Watanabe S, Yoshida T, Kawakami H, Takegawa N, Tanizaki J, Hayashi H, Takeda M, Yonesaka K, Tsurutani J, Nakagawa K.

Mol Cancer Ther. 2017 Nov;16(11):2563-2571. doi: 10.1158/1535-7163.MCT-17-0351. Epub 2017 Aug 24.

PMID:
28839001
8.

Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement.

Nagashima Y, Yoshino S, Yamamoto S, Maeda N, Azumi T, Komoike Y, Okuno K, Iwasa T, Tsurutani J, Nakagawa K, Masaaki O, Hiroaki N.

Mol Clin Oncol. 2017 Sep;7(3):359-366. doi: 10.3892/mco.2017.1346. Epub 2017 Jul 25.

9.

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.

Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J.

Int J Cancer. 2017 Oct 15;141(8):1682-1689. doi: 10.1002/ijc.30870. Epub 2017 Jul 12.

PMID:
28677116
10.

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.

Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, Takahashi M, Saito T, Tsurutani J, Mukai H, Yoshinami T, Takao S, Yamamoto Y, Matsuoka T, Iwase H, Iwata H, Nakamura S, Saeki T.

Invest New Drugs. 2017 Dec;35(6):791-799. doi: 10.1007/s10637-017-0486-4. Epub 2017 Jun 29.

11.

Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.

Yamamura J, Masuda N, Yamamoto D, Tsuyuki S, Yamaguchi M, Tanaka S, Tsurutani J, Tokunaga S, Yoshidome K, Mizutani M, Aono T, Ooe A, Tanino H, Matsunami N, Yasojima H, Nakayama T, Nishida Y.

Chemotherapy. 2017;62(5):307-313. doi: 10.1159/000475879. Epub 2017 Jun 13.

PMID:
28605730
12.

Incidence of carnitine deficiency in patients with cancer pain: A pilot study.

Sakai K, Matsuoka H, Ohtake Y, Makimura C, Izumi H, Fujita Y, Otsuka M, Tsurutani J, Nishio K, Nakagawa K, Koyama A.

Mol Clin Oncol. 2017 Mar;6(3):331-333. doi: 10.3892/mco.2017.1159. Epub 2017 Feb 7.

13.

Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine.

Matsuoka H, Yoshiuchi K, Koyama A, Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.

Int J Behav Med. 2017 Aug;24(4):535-541. doi: 10.1007/s12529-017-9644-5.

14.

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.

Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.

Oncotarget. 2016 Dec 20;7(51):84860-84871. doi: 10.18632/oncotarget.12743.

15.

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.

Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K.

Invest New Drugs. 2016 Jun;34(3):347-54. doi: 10.1007/s10637-016-0347-6. Epub 2016 Mar 22.

16.

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.

Aihara T, Toyama T, Takahashi M, Yamamoto Y, Hara F, Akabane H, Fujisawa T, Ishikawa T, Nagai S, Nakamura R, Tsurutani J, Ito Y, Mukai H.

Breast Cancer. 2016 May;23(3):329-42. doi: 10.1007/s12282-016-0670-y. Epub 2016 Feb 24. No abstract available.

PMID:
26910609
17.

Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.

Watanabe S, Takeda M, Takahama T, Iwasa T, Tsurutani J, Tanizaki J, Shimizu T, Sakai K, Wada Y, Isogai N, Nishio K, Nakagawa K.

Invest New Drugs. 2016 Jun;34(3):394-6. doi: 10.1007/s10637-016-0329-8. Epub 2016 Feb 9.

PMID:
26856856
18.

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.

Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K.

Oncotarget. 2016 Jan 19;7(3):3453-60. doi: 10.18632/oncotarget.6498.

19.

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.

Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group.

Lancet Oncol. 2016 Jan;17(1):90-8. doi: 10.1016/S1470-2045(15)00411-8. Epub 2015 Nov 27.

PMID:
26617202
20.

Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.

Nonagase Y, Okamoto K, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Shimizu T, Tsurutani J, Nakagawa K.

Anticancer Drugs. 2016 Mar;27(3):251-3. doi: 10.1097/CAD.0000000000000317.

PMID:
26575001
21.

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.

Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K.

PLoS One. 2015 May 8;10(5):e0121891. doi: 10.1371/journal.pone.0121891. eCollection 2015.

22.

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.

Tsurutani J, Kuroi K, Iwasa T, Miyazaki M, Nishina S, Makimura C, Tanizaki J, Okamoto K, Yamashita T, Aruga T, Shigekawa T, Komoike Y, Saeki T, Nakagawa K.

Cancer Sci. 2015 Jun;106(6):734-9. doi: 10.1111/cas.12658. Epub 2015 Apr 9.

23.

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K.

Br J Cancer. 2015 Mar 3;112(5):819-24. doi: 10.1038/bjc.2015.10. Epub 2015 Feb 5.

24.

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.

Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, Nakagawa K.

Invest New Drugs. 2015 Apr;33(2):380-8. doi: 10.1007/s10637-014-0196-0. Epub 2014 Dec 12.

25.

Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.

Okamoto I, Miyazaki M, Takeda M, Terashima M, Azuma K, Hayashi H, Kaneda H, Kurata T, Tsurutani J, Seto T, Hirai F, Konishi K, Sarashina A, Yagi N, Kaiser R, Nakagawa K.

J Thorac Oncol. 2015 Feb;10(2):346-52. doi: 10.1097/JTO.0000000000000395.

26.

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer.

Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S; Japanese Breast Cancer Society.

Breast Cancer. 2015 Jan;22(1):5-15. doi: 10.1007/s12282-014-0563-x. Epub 2014 Sep 9. No abstract available.

PMID:
25200171
27.

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.

Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K.

Springerplus. 2014 Aug 8;3:417. doi: 10.1186/2193-1801-3-417. eCollection 2014.

28.

Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.

Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K.

PLoS One. 2014 Jul 14;9(7):e101902. doi: 10.1371/journal.pone.0101902. eCollection 2014.

29.

Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.

Takashima T, Nakayama T, Yoshidome K, Kawajiri H, Kamigaki S, Tsurutani J, Arai T, Ito T, Komoike Y, Doi T, Masuda N, Miyauchi K, Miyoshi Y, Sakamoto J, Morita S, Taguchi T.

Anticancer Res. 2014 Jul;34(7):3583-8.

PMID:
24982373
30.

Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.

Kurata T, Tsurutani J, Fujisaka Y, Okamoto W, Hayashi H, Kawakami H, Shin E, Hayashi N, Nakagawa K.

Invest New Drugs. 2014 Oct;32(5):946-54. doi: 10.1007/s10637-014-0112-7. Epub 2014 May 31.

PMID:
24875132
31.

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.

Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.

Breast. 2014 Aug;23(4):466-72. doi: 10.1016/j.breast.2014.03.008. Epub 2014 Apr 16.

PMID:
24742606
32.

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.

Kawabata S, Chiang CT, Tsurutani J, Shiga H, Arwood ML, Komiya T, Gills JJ, Memmott RM, Dennis PA.

Oncotarget. 2014 Feb 28;5(4):1062-70.

33.

Regression of brain metastases from breast cancer with eribulin: a case report.

Matsuoka H, Tsurutani J, Tanizaki J, Iwasa T, Komoike Y, Koyama A, Nakagawa K.

BMC Res Notes. 2013 Dec 18;6:541. doi: 10.1186/1756-0500-6-541.

34.

[Discussion about Biomilar development: Filgrastim BS injection and its applications in clinical practice].

Saeki T, Tokuda Y, Takigawa N, Tsurutani J.

Gan To Kagaku Ryoho. 2013 Oct;40(10):1365-76. Japanese. No abstract available.

PMID:
24312985
35.

[Resistant mechanisms against breast cancer treatment and therapeutic strategies].

Tanizaki J, Tsurutani J.

Nihon Rinsho. 2012 Nov;70 Suppl 8:336-40. Japanese. No abstract available.

PMID:
23513862
36.

Perspectives in drug development for cancer therapy in Asia.

Nakagawa K, Tsurutani J.

Chin Clin Oncol. 2012 Dec;1(2):17. doi: 10.3978/j.issn.2304-3865.2012.11.12. No abstract available.

37.

A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.

Hasegawa Y, Okamoto I, Takezawa K, Miyazaki M, Tsurutani J, Yonesaka K, Morinaga R, Tsuya A, Terashima M, Kudoh T, Azuma K, Kurata T, Nishikawa T, Fukuoka M, Nishimura Y, Nakagawa K.

Invest New Drugs. 2013 Jun;31(3):599-604. doi: 10.1007/s10637-012-9833-7. Epub 2012 May 24.

PMID:
22623066
38.

Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.

Matsuoka H, Makimura C, Koyama A, Otsuka M, Okamoto W, Fujisaka Y, Kaneda H, Tsurutani J, Nakagawa K.

Anticancer Res. 2012 May;32(5):1805-9.

PMID:
22593465
39.

NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.

Azuma K, Kawahara A, Hattori S, Taira T, Tsurutani J, Watari K, Shibata T, Murakami Y, Takamori S, Ono M, Izumi H, Kage M, Yanagawa T, Nakagawa K, Hoshino T, Kuwano M.

J Thorac Oncol. 2012 May;7(5):779-89. doi: 10.1097/JTO.0b013e31824c92b4.

40.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
41.

Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.

Matsuoka H, Arao T, Makimura C, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Tanigawara Y, Yamanaka T, Tanaka K, Nishio K, Nakagawa K.

Oncol Rep. 2012 May;27(5):1393-9. doi: 10.3892/or.2012.1660. Epub 2012 Jan 26.

PMID:
22293824
42.

Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.

Makimura C, Arao T, Matsuoka H, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Yamanaka T, Tanaka K, Nishio K, Nakagawa K.

Anticancer Res. 2011 Dec;31(12):4561-8.

PMID:
22199331
43.

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.

Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, Morinaga R, Terashima M, Miyazaki M, Okamoto I, Nishida Y, Tominaga S, Tokunaga Y, Yamaguchi M, Sakamoto J, Nakayama T, Nakagawa K.

Breast Cancer. 2013 Apr;20(2):131-6. doi: 10.1007/s12282-011-0316-z. Epub 2011 Nov 29.

PMID:
22124996
44.

Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance.

Zhang C, Elkahloun AG, Robertson M, Gills JJ, Tsurutani J, Shih JH, Fukuoka J, Hollander MC, Harris CC, Travis WD, Jen J, Dennis PA.

PLoS One. 2011;6(8):e23849. doi: 10.1371/journal.pone.0023849. Epub 2011 Aug 24.

45.

Transient effectiveness of an oral 5-Fluorouracil derivative, s-1, for epirubicin, cyclophosphamide and Paclitaxel refractory skin metastases from possible occult breast cancer in a male.

Hirao A, Oiso N, Tsurutani J, Kimura M, Watatani M, Nakagawa K, Kawada A.

Case Rep Dermatol. 2011 Feb 23;3(1):42-8. doi: 10.1159/000325069.

46.

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.

Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, Arao T, Satoh T, Okamoto I, Kurata T, Nishio K, Nakagawa K.

Biochem Biophys Res Commun. 2011 Apr 1;407(1):219-24. doi: 10.1016/j.bbrc.2011.03.002. Epub 2011 Mar 4.

PMID:
21377448
47.

High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.

Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K.

Int J Clin Oncol. 2011 Jun;16(3):244-9. doi: 10.1007/s10147-010-0170-6. Epub 2011 Jan 18.

PMID:
21243395
48.

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.

Okamoto I, Shimizu T, Miyazaki M, Tsurutani J, Ichikawa Y, Terashima M, Takeda M, Fumita S, Ohki E, Kimura N, Hashimoto J, Nakagawa K.

Invest New Drugs. 2012 Apr;30(2):639-46. doi: 10.1007/s10637-010-9565-5. Epub 2010 Oct 20.

49.

A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).

Kurata T, Yamamoto N, Komiya T, Tsurutani J, Miyazaki M, Tamura K, Takeda K, Nakagawa K, Fukuoka M.

Jpn J Clin Oncol. 2010 Oct;40(10):992-4. doi: 10.1093/jjco/hyq079. Epub 2010 Jun 3.

PMID:
20522445
50.

Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.

Okamoto I, Takeda K, Daga H, Miyazaki M, Yonesaka K, Kiyota H, Tsurutani J, Ueda S, Ichikawa Y, Takeda M, Sekiguchi R, Tominaga K, Enatsu S, Nambu Y, Nakagawa K.

Lung Cancer. 2010 Nov;70(2):168-73. doi: 10.1016/j.lungcan.2010.02.007. Epub 2010 Mar 16.

PMID:
20236726

Supplemental Content

Loading ...
Support Center